Insight Molecular Diagnostics Inc.: total liabilities
Total liabilities for Insight Molecular Diagnostics Inc. Inspect selected reporting periods, original units and SEC filing links; download the financial history.
All Insight Molecular Diagnostics Inc. financial histories
What this measure means
Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.
Exact concept: us-gaap:Liabilities. Each value is a balance at the reporting date, not a flow earned over a year. Different units remain separate; no currency conversion or interpolation is applied.
Coverage of this history
Selected reporting periods run from 2015-12-31 to 2025-12-31. The SEC response was captured on 2026-09-21.
Selected filing history
| Period start | Period end | Value | Unit | Filed | Source filing |
|---|---|---|---|---|---|
| At date | 2025-12-31 | 57,220,000 | USD | 2026-03-26 | 10-K · 0001642380-26-000004 |
| At date | 2024-12-31 | 47,355,000 | USD | 2026-03-26 | 10-K · 0001642380-26-000004 |
| At date | 2023-12-31 | 49,298,000 | USD | 2025-03-24 | 10-K · 0000950170-25-043852 |
| At date | 2022-12-31 | 60,497,000 | USD | 2024-04-16 | 10-K · 0001493152-24-014720 |
| At date | 2021-12-31 | 94,346,000 | USD | 2023-04-12 | 10-K · 0001493152-23-012005 |
| At date | 2020-12-31 | 21,936,000 | USD | 2022-03-11 | 10-K · 0001493152-22-006677 |
| At date | 2019-12-31 | 9,021,000 | USD | 2021-03-19 | 10-K · 0001493152-21-006465 |
| At date | 2018-12-31 | 6,095,000 | USD | 2020-03-26 | 10-K · 0001493152-20-004738 |
| At date | 2017-12-31 | 5,813,000 | USD | 2019-04-01 | 10-K · 0001493152-19-004549 |
| At date | 2016-12-31 | 4,585,000 | USD | 2018-04-02 | 10-K · 0001140361-18-016477 |
| At date | 2015-12-31 | 2,314,000 | USD | 2017-02-27 | 10-K · 0001140361-17-009369 |
Related financial histories
- Insight Molecular Diagnostics Inc.: total assets
- Insight Molecular Diagnostics Inc.: stockholders equity
- Insight Molecular Diagnostics Inc.: cash and cash equivalents
- Insight Molecular Diagnostics Inc.: net income or loss
- Insight Molecular Diagnostics Inc.: operating cash flow
- Insight Molecular Diagnostics Inc.: capital expenditure payments
- Insight Molecular Diagnostics Inc.: contract revenue excluding tax
- Insight Molecular Diagnostics Inc.: financing cash flow
- Insight Molecular Diagnostics Inc.: investing cash flow
- Insight Molecular Diagnostics Inc.: retained earnings or deficit
- Insight Molecular Diagnostics Inc.: basic weighted-average shares
- Insight Molecular Diagnostics Inc.: diluted weighted-average shares
- Insight Molecular Diagnostics Inc.: basic earnings per share
- Insight Molecular Diagnostics Inc.: diluted earnings per share
- Insight Molecular Diagnostics Inc.: income tax expense or benefit
- Insight Molecular Diagnostics Inc.: net property, plant and equipment
- Insight Molecular Diagnostics Inc.: share-based compensation expense
- Insight Molecular Diagnostics Inc.: operating income or loss
- Insight Molecular Diagnostics Inc.: current assets
- Insight Molecular Diagnostics Inc.: interest expense
- Insight Molecular Diagnostics Inc.: current liabilities
- Insight Molecular Diagnostics Inc.: current accounts payable
- Insight Molecular Diagnostics Inc.: goodwill carrying amount
- Insight Molecular Diagnostics Inc.: net finite-lived intangible assets
- Insight Molecular Diagnostics Inc.: net current accounts receivable
- Insight Molecular Diagnostics Inc.: operating expenses
- Insight Molecular Diagnostics Inc.: gross profit
- Insight Molecular Diagnostics Inc.: cost of revenue
- Insight Molecular Diagnostics Inc.: research and development expense
Inspect the source
- Entity
- Insight Molecular Diagnostics Inc. / CIK 0001642380
- Captured
- 2026-09-21T17:22:58.445Z
- SEC response SHA-256
0a6761cf94e28474363a8a78b49cfef33865938d1402e981fe1319a8439212bf
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001642380.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))